Lytix Biopharma AS

OB:LYTIX Stock Report

Market Cap: kr317.5m

Lytix Biopharma Management

Management criteria checks 2/4

Lytix Biopharma's CEO is Oystein Rekdal, appointed in Jan 2003, has a tenure of 21.42 years. total yearly compensation is NOK4.77M, comprised of 72.7% salary and 27.3% bonuses, including company stock and options. directly owns 0.28% of the company’s shares, worth NOK895.75K. The average tenure of the management team and the board of directors is 5.1 years and 3 years respectively.

Key information

Oystein Rekdal

Chief executive officer

kr4.8m

Total compensation

CEO salary percentage72.7%
CEO tenure21.4yrs
CEO ownership0.3%
Management average tenure5.1yrs
Board average tenure3yrs

Recent management updates

Recent updates

We're A Little Worried About Lytix Biopharma's (OB:LYTIX) Cash Burn Rate

Mar 02
We're A Little Worried About Lytix Biopharma's (OB:LYTIX) Cash Burn Rate

We're Keeping An Eye On Lytix Biopharma's (OB:LYTIX) Cash Burn Rate

Oct 04
We're Keeping An Eye On Lytix Biopharma's (OB:LYTIX) Cash Burn Rate

We Think Lytix Biopharma (OB:LYTIX) Can Afford To Drive Business Growth

Jun 21
We Think Lytix Biopharma (OB:LYTIX) Can Afford To Drive Business Growth

Companies Like Lytix Biopharma (OB:LYTIX) Are In A Position To Invest In Growth

Jan 11
Companies Like Lytix Biopharma (OB:LYTIX) Are In A Position To Invest In Growth

We're Not Very Worried About Lytix Biopharma's (OB:LYTIX) Cash Burn Rate

Jul 16
We're Not Very Worried About Lytix Biopharma's (OB:LYTIX) Cash Burn Rate

We're Not Very Worried About Lytix Biopharma's (OB:LYTIX) Cash Burn Rate

Jan 25
We're Not Very Worried About Lytix Biopharma's (OB:LYTIX) Cash Burn Rate

We Think Lytix Biopharma (OB:LYTIX) Can Afford To Drive Business Growth

Sep 14
We Think Lytix Biopharma (OB:LYTIX) Can Afford To Drive Business Growth

CEO Compensation Analysis

How has Oystein Rekdal's remuneration changed compared to Lytix Biopharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023kr5mkr3m

-kr88m

Sep 30 2023n/an/a

-kr99m

Jun 30 2023n/an/a

-kr91m

Mar 31 2023n/an/a

-kr60m

Dec 31 2022kr4mkr4m

-kr56m

Sep 30 2022n/an/a

-kr43m

Jun 30 2022n/an/a

-kr51m

Mar 31 2022n/an/a

-kr63m

Dec 31 2021kr8mkr7m

-kr48m

Sep 30 2021n/an/a

-kr44m

Jun 30 2021n/an/a

-kr40m

Mar 31 2021n/an/a

-kr35m

Dec 31 2020kr7mkr4m

-kr42m

Dec 31 2019kr2mkr2m

-kr33m

Dec 31 2018kr2mkr2m

-kr62m

Dec 31 2017kr2mkr2m

-kr69m

Compensation vs Market: Oystein's total compensation ($USD454.04K) is above average for companies of similar size in the Norwegian market ($USD331.41K).

Compensation vs Earnings: Oystein's compensation has increased whilst the company is unprofitable.

CEO

Oystein Rekdal

21.4yrs

Tenure

kr4,765,000

Compensation

Dr. Oystein Rekdal, Ph.D. co-founded Lytix Biopharma AS in 2003 and serves as its Chief Executive Officer since September 11, 2019. Dr. Rekdal was Chief Scientific Officer of Lytix Biopharma AS since April...

Leadership Team

NamePositionTenureCompensationOwnership
Oystein Rekdal
Co-Founder & CEO21.4yrskr4.77m0.28%
NOK 895.7k
Gjest Breistein
Chief Financial Officer5.8yrsno data0.022%
NOK 71.1k
Gry Stensrud
Chief Technology Officer3.3yrsno data0.010%
NOK 32.0k
Baldur Sveinbjørnsson
Chief Scientific Officer4.5yrsno data0.0086%
NOK 27.4k
Ole Nordby
Head of IR & Communication Managerno datano datano data
Jacqueline Earabino
Head of Clinical Operationsno datano datano data

5.1yrs

Average Tenure

Experienced Management: LYTIX's management team is seasoned and experienced (5.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Sudhir Agrawal
Member of Scientific Advisory Boardno datano datano data
Kjetil Hestdal
Non-Executive Independent Director3yrskr331.00kno data
James Allison
Member of Scientific Advisory Board5yrsno datano data
Brynjar Forbergskog
Non-Executive Independent Director3yrskr331.00kno data
Jayson Rieger
Non-Executive Independent Director3yrskr331.00kno data
Marie Roskrow
Chairperson1.2yrskr91.00kno data
Padmanee Sharma
Member of Scientific Advisory Board5yrsno datano data
Marie-Louise Fjallskog
Interim CMO & Director3yrskr331.00kno data
Aurelien Marabelle
Member of Scientific Advisory Boardno datano datano data
Robert H.I. Andtbacka
Member of Scientific Advisory Boardno datano datano data
Sandra Demaria
Member of Scientific Advisory Boardno datano datano data
Evelina Vagesjo
Non-Executive Independent Director3yrskr331.00kno data

3.0yrs

Average Tenure

64yo

Average Age

Experienced Board: LYTIX's board of directors are considered experienced (3 years average tenure).

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.